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Abstract
Introduction: Vitamin D receptor (VDR) is encoded by the VDR gene. Several studies have supported that this gene is associated with 
diabetes. Heterodimer VDR/RXR functions as an enhancer of the BGLAP gene and increases the basal transcription rate of osteocalcin 
(OC) during osteoblast differentiation. OC is a regulator of glucose metabolism in mice. Moreover, OC level is decreased in patients with 
type 2 diabetes (T2D). Although inversely correlated with serum glucose insulin and glycated haemoglobin, it is unclear whether OC 
reduction is caused by diabetes or plays a role in the pathogenesis and/or progression of the disease.
In this study we analysed the association between TaqI and ApaI VDR gene polymorphisms and OC serum concentration in T2D subjects. 
Material and methods: Patients underwent clinical and nutritional assessment. Genomic DNA was extracted from leucocytes using 
a standard salting-out procedure. The polymorphisms were genotyped by PCR-RFLP method. ELISA was used to measure OC and 
insulin concentrations. 
Results: Association between TT genotype of TaqI polymorphism and low levels of OC was observed only in the population with over-
weight and obesity. No association between TaqI and ApaI polymorphisms and T2D was observed (p > 0.05). Furthermore, in T2D subjects, 
no correlation between ApaI and TaqI genotypes and age, sex, Body Mass Index (BMI), glucose, or OC was observed. 
Conclusions: The TT genotype of TaqI VDR gene polymorphism was correlated with low levels of OC in overweight and obese subjects. 
However, TaqI and ApaI VDR gene polymorphisms were not associated with T2D.  (Endokrynol Pol 2015; 66 (4): 329–333)
Key words: VDR; osteocalcin; genotypes; polymorphisms; T2D
Streszczenie
Wstęp: Receptor witaminy D (VDR) kodowany jest przez gen VDR. Kilka badań potwierdziło, że gen ten jest związany z cukrzycą. 
Heterodimer VDR/RXR funkcjonuje jako stymulator genu BGLAP i zwiększa podstawowy wskaźnik transkrypcji osteokalcyny (OC) 
podczas różnicowania osteoblastów. Osteokalcyna jest regulatorem metabolizmu glukozy u myszy. Ponadto, stężenie OC jest obniżone 
u pacjentów z cukrzycą typu 2 (T2D). Pomimo odwrotnej korelacji między stężeniem OC a stężeniem glukozy i insuliny w surowicy, 
a także hemoglobiną glikowaną, nie jest wiadome czy obniżenie stężenia OC jest wywołane przez cukrzycę lub odgrywa rolę w patoge-
nezie i/lub progresji choroby.
W niniejszym badaniu autorzy przeanalizowali związek pomiędzy polimorfizmami genów VDR TaqI oraz ApaI, a także stężenie OC 
w surowicy u pacjentów z T2D.
Materiał i metody: Pacjentów poddano ocenie klinicznej i żywieniowej. Genomowe DNA pobrano z leukocytów dzięki standardowej 
procedurze wysalania. Polimorfizmy genotypowano metodą PCR-RFLP. Testem ELISA zmierzono stężenia OC oraz insuliny.
Wyniki: Związek pomiędzy genotypem TT polimorfizmu TaqI a niskim stężeniem OC zaobserwowano jedynie u populacji z nadwagą 
i otyłością. Nie wykazano związku pomiędzy polimorfizmami TaqI i ApaI oraz T2D (p > 0,05). Co więcej, u pacjentów z T2D nie wykazano 
korelacji pomiędzy genotypami ApaI i TaqI oraz wiekiem, płcią, wskaźnikiem masy ciała (BMI), glukozą lub OC.
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Introduction
Type 2 diabetes mellitus (T2D) is a public health prob-
lem. It is estimated that there are over 347 million people 
living with diabetes worldwide, most of them having 
T2D [1]. T2D is a leading cause of premature death, 
mainly from cardiovascular disease [2].
Furthermore, T2D seems to be influenced by ge-
netic factors [3]. Several genetic polymorphisms have 
been studied to explain this genetic susceptibility, for 
example genes associated with oxidative stress, growth 
factors, and bone mineral density, among others (Mark 
I et al. 2010). 
Among these polymorphisms, genes associated 
with vitamin D metabolism have emerged as inter-
esting candidates to be studied in the context of T2D 
T2D development because Vitamin D not only affects 
calcium metabolism, but also immunomodulation and 
insulin secretion [4].
The VDR gene encodes vitamin D receptor (VDR). 
Certain allelic variants in VDR have been related to dia-
betes. In a German population, combinations of BsmI/
ApaI/TaqI influenced susceptibility to type 1 diabetes 
(T1D) [5]. In a Taiwanese population the AA genotype 
of ApaI polymorphism was associated with T1D. The 
aa genotype of ApaI has been associated with defective 
insulin secretion in Bangladeshi Asians, a population 
that have an increased risk of having T2D (Ogunkolade 
BW et al. 2002). These findings suggest that the VDR 
gene may contribute to susceptibility in both T1D and 
T2D. However, there is no data reporting its direct 
causality in T2D. 
VDR forms a heterodimer with the retinoid X 
receptor (RXR) that binds to the vitamin D response 
element (VDRE) in the promoter region of the BGLAP 
gene to enhance its transcription [6]. It has been de-
scribed that the coexistence of the TaqI T/C (rs731236) 
polymorphism and the ApaI G/T (rs 7975232) poly-
morphism result in marked linkage disequilibrium. 
This may affect one of the zinc fingers of the nuclear 
signalling heterodimer that binds to VDRE [7]. VDRE/
VDR/RXR complex is associated with an increase 
osteocalcin (OC) basal transcription rate during os-
teoblast differentiation [7].
The OC peptide is encoded by the BGLAP gene 
[8]. A biological variant of OC has been described to 
be a regulator of glucose metabolism in mice, while its 
expression seems to be reduced in humans with T2D 
[9]. Although inversely correlated with serum glucose, 
Wnioski: Genotyp TT polimorfizmu genu VDR TaqI jest skorelowany z niskim stężeniem OC u pacjentów z nadwagą i otyłością. Jednakże, 
polimorfizmy genu VDR TaqI i ApaI nie są związane z T2D.  (Endokrynol Pol 2015; 66 (4): 329–333)
Słowa kluczowe: VDR; osteokalcyna; genotypy; polimorfizmy; T2D
insulin levels, and glycated haemoglobin, it is unclear 
whether the OC underexpression is caused by diabetes 
or if it plays a role in the pathogenesis and/or progres-
sion of the disease [10].
Since both VDR and OC are somehow related to 
the metabolic alterations present in T2D, it is reason-
able to hypothesise that VDR polymorphisms could 
confer susceptibility to T2D and alter the OC con-
centration levels. This physiological axis correlating 
VDR polymorphisms and OC concentration has not 
been studied in T2D. 
In this study we analysed the association between 
TaqI and ApaI VDR polymorphisms in relation to OC 
serum concentration in patients with T2D.
Material and methods
Subjects
In a case-control study, a total of 125 patients with T2D 
(63 women and 62 men) and 125 healthy subjects (HS) 
(85 women and 40 men) were recruited consecutively 
at the program for detection and treatment of metabolic 
disease in the Molecular Biology Department of the 
University of Guadalajara, Mexico. All Subjects included 
in the study were living on the western of Mexico at 
the time of the study. The study was approved by the 
Ethics, Biosecurity, and Research committee of the 
University Centre for Health Sciences of the Univer-
sity of Guadalajara, and written an informed consent 
was obtained from all participants. Patients that were 
included had the following characteristics: T2D patients 
and HS between 30 and 60 years old, both genders, not 
using drugs such as insulin, vitamin D, vitamin K, thia-
zolidinediones, thiazides, bisphosphonates, coumarin, 
steroids, oral contraceptives, and calcium. Subjects 
with haemolysed serum samples, loss of laboratory 
results, or insufficient blood sample were excluded. The 
medical history of all subjects included in the study was 
obtained and a physical examination was performed. 
Height was measured with a stadiometer (SECA Inc., 
DF, Mexico), and body composition was analysed by 
bioimpedance (Body Composition Analyzer, TBF-300A, 
TANITA Inc., IL, USA). Blood samples were collected 
after overnight fasting in dry tubes for biochemical 
analysis of glucose, total cholesterol, triglycerides, HDL-
c, and VLDL-c using enzymatic colorimetric methods 
(Biosystems, BCN, Spain); insulin (ALPCO diagnostic, 
MA, USA) and total OC, (TakaraBio Inc., Shiga, Japan) 
were measured by ELISA method.
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Genotyping
Blood samples were collected after overnight fasting in 
EDTA-coated tubes for genotyping. Genomic DNA was 
extracted from peripheral blood samples according to 
the Miller method [11]. ApaI SNP in intron 8 and TaqI 
SNP in exon 9 (ATT-ATC, Ile352Ile) of the VDR gene 
were examined by polymerase chain reaction/restric-
tion fragment-length polymorphisms (PCR-RFLPs). 
The PCR for amplification of both polymorphisms was 
conducted with single pair primers designed for the 
proximity between polymorphic sites. These primers 
were, forward: 5’GGGATGGACAGAGCATGG3’, and 
reverse: 5’CCACCTCCCCTATCCACC3’. PCR was per-
formed in a final volume of 50 µL, containing 500 ng 
of gDNA, 20 µM of each primer, 1.5 U/µL Dream 
Taq polymerase (Fermentas, Thermo Sicentific, MA, 
USA), 2.5 µL of 10X buffer, and 2.5 mM of each dNTP 
(Dongsheng Biotech Co., Guangdong, China). The 
amplification was performed on a programmable 
thermocycler (Techne TC-300, Staffs, UK). The frag-
ments obtained were analysed on 2% agarose gel. 
Twenty microlitres of the amplified fragment and were 
incubated with 3U ApaI restriction enzyme and 20 µl 
with 3U TaqI enzyme in a thermal bath according to 
the supplier’s specifications. PCR fragments and diges-
tion products were analysed in 2% agarose gel stained 
with Gel Red™ (Biotium, Inc., CA, USA). Genotyping 
was done in duplicates.
Genotypes were designated conventionally by the 
first letter of the name of the enzyme. A capital letter 
indicates the absence of the cut site, whereas a lower-
case letter indicates its presence. 
For haplotype analysis, SNPStats software was 
used [12].
Statistical analyses
Genotype and allele frequencies of differences between 
groups were tested using Chi-square test (χ2) and odds 
ratio (OR) with 95% confidence interval (MedCalc™ 
Statistical Software). A Student t test was used for two-
group means comparison, and one-way ANOVA was 
used to compare the laboratorial and clinical assessment 
according to each genotype. Logistic regression analysis 
was performed to evaluate associations between clini-
cal and genetic parameters. Ages were adjusted using 
Kruskal-Wallis regression and then compared using 
the Chi-square test (χ2). Probability (P) values < 0.05 
were considered significant. Statistical analyses were 
performed with SSPS 20 software (IBM©, NY, USA).
Results
The basal characteristics of the studied population are 
show in Table I. 
The genotypic and allelic distributions are shown 
in Table II. No significant differences between T2D and 
HS in the genotypic frequencies of TaqI (p = 0.061) and 
ApaI (p = 0.98) SNPs were observed. Both allele and 
genotype proportions were in equilibrium according 
to Hardy-Weinberg’s law. 
VLDL-c, total cholesterol, and triglycerides were 
significantly different in T2D compared to HS (44.8 ± 
± 28.5 vs. 40 ± 5, (p < 0.05), 206.8 ± 67.4 vs. 180.8 ± 53.8, 
(p < 0.01), 224.8 ± 140.8 vs. 165.2 ± 108.5, (p < 0.01), 
respectively.
In T2D patients, no significant differences in age, 
gender, body mass index (BMI), glucose, and OC con-
centration according to genotypes in TaqI and ApaI were 
observed (Table III). 
Table I. Clinical and biochemical characteristics in the 
studied population
Tabela I. Cechy kliniczne i biochemiczne badanej populacji
T2D 
(n = 125)
HS 
(n = 125)
p*
Gender Female n (%) 63 (50.4) 85 (68)
Male n (%) 62 (49.6) 40 (32)
Age (years) 50.8 ± 7.3 44.5 ± 8.2 0.001
BMI [kg/m2] 29.6 ± 6.4 28.4 ± 6.2 0.07
Glucose [mg/dL] 181.1 ± 74.8 84 ± 14.5 0.001
VLDL-c [mg/dL] 44.8 ± 28.5 32 ± 19.5 0.04
Total cholesterol [mg/dL] 206.8 ± 67.4 180.8 ± 53.8 0.006
Triglycerides [mg/dL] 224.8 ± 140.8 165.2 ± 108.5 0.01
OC [ng/mL] 6.61 ± 3.5 10.8 ± 6.5 0.008
BMI — Body mass index; VLDL-c — cholesterol bound to very low density 
lipoproteins; OC — osteocalcin. Values are described as mean ± standard 
deviation. *Age-adjusted Kruskal-Wallis test
Table II. Vitamin D receptor genotypes in T2D and HS
Tabela II. Genotypy receptora witaminy D w T2D i HS
  T2D 
(n = 125) 
n (%)
HS 
(n = 125) 
n (%)
p*
TaqI
TT 38 (30.4) 34 (27.2)
Tt 62 (49.6) 72 (57.6)
tt 25(20) 19 (15.2) 0.061
ApaI
AA 47 (37.6) 31 (24.8)
Aa 64 (51.2) 78 (62.4)
aa 14(11.2) 16 (12.8) 0.981
Genotypes showed Hardy-Weinberg equilibrium; *Chi-squared test
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A model in which the whole study population were 
stratified according to BMI as normal weight (1), over-
weight (2), and obese (3) and its association with the 
TaqI and ApaI genotypes was analysed. In this analysis 
we found that the homozygous TT genotype of TaqI was 
correlated with BMI and serum OC. Since a reference 
baseline concentration for OC has not been described, 
in our case we used the average concentration of OC in 
the control group. A significant correlation (p = 0.025) 
between TT genotype of TaqI polymorphism and lower 
levels of OC (under 10.32 ng/dL) was observed only in 
overweight and obese subjects.
No correlation between waist-to-hip ratio and hap-
lotype was observed.
Discussion
Polymorphisms in the VDR gene may contribute to 
the genetic predisposition to certain diseases. As vi-
tamin D modulates insulin secretion, it is likely that 
genetic variants of the VDR gene may contribute to the 
development of T2D. Since patients with T2D exhibit 
subtle alterations in glucose metabolism long before the 
onset of the disease, genetic factors contributing to its 
pathogenesis or development could be detected early 
in the disease process [13]. Our study not has shown 
a significant association between genotypes of TaqI and 
ApaI and T2D, probably due to the small sample size. 
However, previous studies investigating the association 
among VDR polymorphisms and diabetes risk have 
produced inconsistent results [14]. This biochemical evi-
dence may partially explain our results and even those 
of a meta-analysis of similar works performed in Asia.
Our study suggests that the TaqI polymorphism is 
associated with susceptibility to obesity in subjects with 
T2D. Studies are needed over a larger sample size to 
clarify the role of these VDR gene polymorphisms in T2D. 
In our study, subjects with TT genotype showed higher 
BMI. Previous studies have reported the association be-
tween TT genotype of TaqI polymorphism and obesity. 
This genotype accounted for a difference of about 9 kg 
of body weight in that group of subjects [15]. The patho-
physiological mechanisms of this association remain unex-
plained. There is in vitro evidence that vitamin D directly 
inhibits the differentiation of preadipocytes [16, 17] and 
stimulates the terminal differentiation of adipocytes [18]. 
In addition, vitamin D stimulates the secretion of insulin 
[19] and lipoprotein lipase [20].
It is important to emphasise that genotypic analysis re-
flects an apparent association with BMI and serum OC. 
The TT of TaqI genotype was associated with BMI and 
low levels of OC in overweight and obesity subjects. Our 
results are consistent with data reported by Dilmec F et 
al. [21], who suggests that VDR plays an important role in 
the regulation of lipids, possibly mediated by its activity 
in adipocyte calcium metabolism; therefore, there would 
be an association between bone metabolism and energy 
homeostasis. The clinical relevance of the association of 
lipid profile and the OC is not entirely clear. 
OC metabolic effects may be partially mediated by 
an organ directly involved in insulin secretion, such 
as the pancreas. However, an indirect action mediated 
by adipose tissue and the liver has not been ruled out.
Conclusions
In conclusion, the TT genotype of TaqI VDR gene polymor-
phism was associated with low levels of OC in overweight 
and obese subjects. However, TaqI and ApaI VDR gene 
polymorphisms were not associated with T2D. 
Table III. Vitamin D receptor genotypes and clinical profile of T2D patients
Tabela III. Genotypy receptora witaminy D i profil kliniczny pacjentów chorujących na T2D
Genotype Age 
(years)
BMI 
[kg/m2]
Glucose  
[mg/dL]
OC 
[ng/mL]
N Mean ± SD p* Mean ± SD p* Mean ± SD p* Mean ± SD p*
TaqI
TT 38 51.0 ± 7.9 0.74 29.7 ± 6.9 0.80 188.4 ± 82.8 0.74 8.9 ± 3.2 0.80
Tt 62 49.9 ± 7.3 29.1 ± 6.4 183.5 ± 73.7 9.5 ± 4.7
tt 25 50.9 ± 7.0 28.3 ± 3.6 170.5 ± 75.8 8.2 ± 5.9
ApaI
AA 47 51.3 ± 7.4 0.16 29.6 ± 6.9 0.36 186.2 ± 76.4 0.12 9.1 ± 5.0 0.61
Aa 64 50.5 ± 6.8 28.3 ± 5.2 169.7 ± 72.5 8.7 ± 3.7
aa 14 47.3 ± 8.5 30.9 ± 7.0 216.1 ± 86.3 11.0 ± 4.7
* Age-adjusted Kruskal Wallis test. After adjustment Chi-square was calculated (p)
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